An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

Alisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor. In this phase 2 trial, 57 patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome received alisertib 50 mg BID for 7 days in 21-day cycles. Responses in 6/35 AML patients (17% respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, Stuart L., Fenaux, Pierre, Craig, Michael D., Gyan, Emmanuel, Lister, John, Kassis, Jeannine, Pigneux, Arnaud, Schiller, Gary J., Jung, JungAh, Jane Leonard, E., Fingert, Howard, Westervelt, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110881/
https://www.ncbi.nlm.nih.gov/pubmed/25068104
http://dx.doi.org/10.1016/j.lrr.2014.06.003
_version_ 1782328036872421376
author Goldberg, Stuart L.
Fenaux, Pierre
Craig, Michael D.
Gyan, Emmanuel
Lister, John
Kassis, Jeannine
Pigneux, Arnaud
Schiller, Gary J.
Jung, JungAh
Jane Leonard, E.
Fingert, Howard
Westervelt, Peter
author_facet Goldberg, Stuart L.
Fenaux, Pierre
Craig, Michael D.
Gyan, Emmanuel
Lister, John
Kassis, Jeannine
Pigneux, Arnaud
Schiller, Gary J.
Jung, JungAh
Jane Leonard, E.
Fingert, Howard
Westervelt, Peter
author_sort Goldberg, Stuart L.
collection PubMed
description Alisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor. In this phase 2 trial, 57 patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome received alisertib 50 mg BID for 7 days in 21-day cycles. Responses in 6/35 AML patients (17% response rate with an additional 49% stable disease, 34% transfusion independence) included 1 complete response lasting >1 year. No responses were observed in MDS patients. Adverse events >30% included diarrhea, fatigue, nausea, febrile neutropenia, and stomatitis. Results suggest modest activity in AML, supporting further research to better understand how AAK inhibition may induce leukemic cell senescence.
format Online
Article
Text
id pubmed-4110881
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-41108812014-07-25 An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes Goldberg, Stuart L. Fenaux, Pierre Craig, Michael D. Gyan, Emmanuel Lister, John Kassis, Jeannine Pigneux, Arnaud Schiller, Gary J. Jung, JungAh Jane Leonard, E. Fingert, Howard Westervelt, Peter Leuk Res Rep Article Alisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor. In this phase 2 trial, 57 patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome received alisertib 50 mg BID for 7 days in 21-day cycles. Responses in 6/35 AML patients (17% response rate with an additional 49% stable disease, 34% transfusion independence) included 1 complete response lasting >1 year. No responses were observed in MDS patients. Adverse events >30% included diarrhea, fatigue, nausea, febrile neutropenia, and stomatitis. Results suggest modest activity in AML, supporting further research to better understand how AAK inhibition may induce leukemic cell senescence. Elsevier 2014-07-05 /pmc/articles/PMC4110881/ /pubmed/25068104 http://dx.doi.org/10.1016/j.lrr.2014.06.003 Text en © 2014 The Authors http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Article
Goldberg, Stuart L.
Fenaux, Pierre
Craig, Michael D.
Gyan, Emmanuel
Lister, John
Kassis, Jeannine
Pigneux, Arnaud
Schiller, Gary J.
Jung, JungAh
Jane Leonard, E.
Fingert, Howard
Westervelt, Peter
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
title An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
title_full An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
title_fullStr An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
title_full_unstemmed An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
title_short An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
title_sort exploratory phase 2 study of investigational aurora a kinase inhibitor alisertib (mln8237) in acute myelogenous leukemia and myelodysplastic syndromes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110881/
https://www.ncbi.nlm.nih.gov/pubmed/25068104
http://dx.doi.org/10.1016/j.lrr.2014.06.003
work_keys_str_mv AT goldbergstuartl anexploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT fenauxpierre anexploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT craigmichaeld anexploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT gyanemmanuel anexploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT listerjohn anexploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT kassisjeannine anexploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT pigneuxarnaud anexploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT schillergaryj anexploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT jungjungah anexploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT janeleonarde anexploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT fingerthoward anexploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT westerveltpeter anexploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT goldbergstuartl exploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT fenauxpierre exploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT craigmichaeld exploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT gyanemmanuel exploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT listerjohn exploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT kassisjeannine exploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT pigneuxarnaud exploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT schillergaryj exploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT jungjungah exploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT janeleonarde exploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT fingerthoward exploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes
AT westerveltpeter exploratoryphase2studyofinvestigationalauroraakinaseinhibitoralisertibmln8237inacutemyelogenousleukemiaandmyelodysplasticsyndromes

Ejemplares similares